semaglutide tirzepatide comparison vs Tirzepatide vs semaglutide and liraglutide

Although the FDA has not approved it specifically for weight loss, research indicates that it may support weight reduction

without health screening examination data ( n =62,007)

About one-third of participants lost 20 percent or more. LaValle explains that the 16.6 percent average weight loss seen with the Wegovy pill reflects several factors, including the higher 25 mg dose, the 64-week length of the trial, the diet and activity coaching participants received and the strong biological effects of semaglutide as a GLP-1

Obesity is a chronic disease, and ongoing medical supervision supports better long-term outcomes